ProfileGDS5678 / 1446631_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 44% 44% 42% 42% 45% 44% 43% 42% 43% 43% 43% 43% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0828945
GSM967853U87-EV human glioblastoma xenograft - Control 23.0156944
GSM967854U87-EV human glioblastoma xenograft - Control 33.0182244
GSM967855U87-EV human glioblastoma xenograft - Control 42.9224942
GSM967856U87-EV human glioblastoma xenograft - Control 52.9237942
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1454945
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0881644
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9802843
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.957442
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9830743
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9974443
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9533243
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0061443
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0052543